PEGylated nanoparticles

Keywords Drug delivery Nanomedicine Nanoparticle PEGylated drug PEGylation... [Pg.115]

Figure 8.3 Schematic representation of the effects of liposome and nanoparticle PEGylation.

Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 2011 6 715-28. [Pg.461]

The concept of de-PEGylation can be applied to the development of nanoparticle-based drug delivery systems. PEG is used for the modification of liposomes to increase their blood circulation time [38], However, it also prevents cellular uptake, resulting in a decrease in therapeutic efficiency thus, modifications of the liposome surface with PEG interfere with membrane fusion to the cell membrane and liposome decomposition [39]. One of the possible strategies to solve this problem is to cleave the PEG chains after the nanoparticle reaches the target site (Fig. 9). This system of de-PEGylation of liposomes is also useful in avoiding the immune... [Pg.123]

Otsuka H, Nagasaki Y, Kataoka K (2003) PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 55 403-419... [Pg.136]

Karakoti AS, Das S, Thevuthasan S, Seal S (2011) PEGylated inorganic nanoparticles. Angew Chem Int Ed Engl 50 1980-1994... [Pg.139]

Ishii T, Otsuka H, Kataoka K, Nagasaki Y (2004) Preparation of functionally Pegylated gold nanoparticles with narrow distribution through autoreduction of auric cation by alpha-biotinyl-PEG-block-[poly (2-(N, N-dimethylamino) ethyl methacrylate)]. Langmuir 20 561-564... [Pg.139]

Miyamoto D, Oishi M, Kojima K, Yoshimoto K, Nagasaki Y (2008) Completely dispersible PEGylated gold nanoparticles under physiological conditions modification of gold nanoparticles with precisely controlled PEG-b-polyamine. Langmuir 24 5010-5017... [Pg.140]

Sun XK, Rossin R, Turner JL, Becker ML, Joralemon MJ, Welch MJ, Wooley KL (2005) An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 6 2541-2554... [Pg.37]

Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, Appel M, d Angelo J, Couvreur P (1999) Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60 121-128. [Pg.313]

Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, Khatri K, Vyas SP (2006) Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 14 45-53 Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA,... [Pg.425]

Glogowski E, Tangirala R, He JB, Russell TP, Emrick T. Miciocapsules of PEGylated gold nanoparticles prepared by fluid-fluid interfacial assembly. Nano Lett 2007 7 389-393. [Pg.200]

Yoncheva, K., Gomez, S., Campanero, M.A., Gamazo, C., Irache, J.M. (2005). Bioadhesive properties of pegylated nanoparticles. Expert Opinion on Drug Delivery, 2, 205-218. [Pg.78]

Peracchia, M., et al. 1998. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res 15 550. [Pg.611]

Calvo, P., et al. 2001. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug... [Pg.611]

Xiong MP, Bae Y, Fukushima S et al (2007) pH-responsive multi-PEGylated dual cationic nanoparticles enable charge modulations for safe gene delivery. ChemMedChem 2 1321—... [Pg.245]

Garinot, M., V. Fievez, et al. (2007). PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 120(3) 195-204. [Pg.165]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...